The PDE8B Gene Striatal Degeneration Genetic Test is a specialized diagnostic assessment available at DNA Labs UAE, designed to detect mutations in the PDE8B gene, which have been associated with striatal degeneration. Striatal degeneration is a neurological condition characterized by the progressive deterioration of the striatum, a critical part of the brain involved in motor control and various cognitive processes. Mutations in the PDE8B gene can lead to disrupted signaling pathways within the brain, contributing to the development of this condition.
This genetic test is crucial for individuals who exhibit symptoms of striatal degeneration or have a family history of the disease, as early detection can aid in the management and treatment of symptoms. The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to identify any genetic alterations in the PDE8B gene.
The cost of the PDE8B Gene Striatal Degeneration Genetic Test at DNA Labs UAE is 4400 AED. This price includes the comprehensive analysis and a detailed report of the findings, which can provide valuable insights for healthcare providers in developing a personalized treatment plan for affected individuals. Given the complexity and the specialized nature of this test, it represents a significant step forward in the field of genetic diagnostics and personalized medicine, offering hope to those affected by striatal degeneration and their families.
The SLC25A19 Gene Thiamine Metabolism Dysfunction Syndrome 4 Progressive Polyneuropathy Type Genetic Test is a specialized diagnostic procedure designed to identify mutations in the SLC25A19 gene, which are associated with Thiamine Metabolism Dysfunction Syndrome 4 (also known as Progressive Polyneuropathy). This condition is a rare genetic disorder that affects the body's ability to metabolize thiamine properly, leading to a range of neurological symptoms including progressive polyneuropathy, characterized by the deterioration of nerve function.
The test is crucial for individuals displaying symptoms related to thiamine metabolism dysfunction, as early detection and management can significantly improve the quality of life. Conducted at DNA Labs UAE, a leading facility in genetic testing, the test involves analyzing the patient's DNA to detect mutations in the SLC25A19 gene that are indicative of the syndrome.
The cost of the test is set at 4400 AED, reflecting the comprehensive nature of the analysis and the specialized expertise required to interpret the results. By providing a definitive diagnosis, this genetic test enables healthcare providers to tailor treatment and management plans specifically for the patient's condition, potentially including thiamine supplementation among other strategies.
Overall, the SLC25A19 Gene Thiamine Metabolism Dysfunction Syndrome 4 Progressive Polyneuropathy Type Genetic Test represents a vital tool in the diagnosis and management of this rare but impactful disorder, offering hope and direction for affected individuals and their families.
The CACNA1S gene plays a crucial role in the normal functioning of skeletal muscle cells. Mutations in this gene can lead to Thyrotoxic Periodic Paralysis Type 1, a condition characterized by episodes of muscle weakness or paralysis, often triggered by high levels of thyroid hormones. This genetic disorder is linked to an abnormal response of muscle cells to potassium levels in the body, particularly during instances of thyrotoxicosis, where excessive thyroid hormone is present.
To diagnose this condition and differentiate it from other forms of periodic paralysis, genetic testing of the CACNA1S gene is essential. DNA Labs UAE offers a comprehensive genetic test specifically designed to identify mutations in the CACNA1S gene associated with Thyrotoxic Periodic Paralysis Type 1. This test is pivotal for confirming the diagnosis, understanding the risk of passing the condition to offspring, and guiding treatment decisions.
The cost of the CACNA1S Gene Thyrotoxic Periodic Paralysis Type 1 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the detailed analysis required to detect the presence of the specific genetic alterations within the CACNA1S gene that cause the disorder. By opting for this test, patients and healthcare providers can gain valuable insights into the genetic basis of the symptoms, enabling personalized management plans that can significantly improve the quality of life for those affected by this condition.
The KCNJ18 gene plays a critical role in the development of Thyrotoxic Periodic Paralysis Type 2 (TPP2), a rare condition that manifests as episodes of muscle weakness in individuals with hyperthyroidism. The genetic test for TPP2 focuses on identifying mutations in the KCNJ18 gene, which can help in diagnosing the condition accurately and facilitating appropriate treatment strategies. Conducted at DNA Labs UAE, this genetic test is priced at 4400 AED. It is a crucial step for individuals exhibiting symptoms of TPP2 or those with a family history of the condition, offering them a clearer understanding of their genetic predisposition and guiding healthcare professionals in tailoring personalized management plans.
The ITPR1 gene is implicated in Spinocerebellar Ataxia Type 29 (SCA29), a rare, congenital, nonprogressive neurological disorder characterized by early-onset ataxia, delayed motor development, and mild cognitive impairment. This condition is inherited in an autosomal dominant pattern, meaning a mutation in just one copy of the gene in each cell is sufficient to cause the disorder. The ITPR1 gene plays a crucial role in calcium signaling within cells, essential for various cellular processes, including coordination and motor control, which are affected in SCA29.
To diagnose SCA29 and confirm its genetic basis, a specific genetic test is available at DNA Labs UAE. This test focuses on identifying mutations in the ITPR1 gene that are responsible for the condition. Given the complexity of genetic testing and the need for precise results, the test is priced at 4400 AED. Conducting this test can provide crucial information for families affected by SCA29, enabling them to understand the genetic underpinnings of the disorder, consider genetic counseling, and make informed decisions regarding management and support for affected family members.
The ATXN3 gene test for Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease, is a crucial diagnostic tool offered by DNA Labs UAE. This genetic test is aimed at detecting mutations in the ATXN3 gene, which are responsible for causing SCA3, a progressive neurodegenerative disorder. Characterized by a wide range of symptoms such as lack of coordination, difficulty with speech, and involuntary eye movements, SCA3 is inherited in an autosomal dominant manner, meaning that having just one copy of the altered gene can lead to the condition.
DNA Labs UAE provides this highly specialized test for a cost of 4400 AED. The test involves analyzing the patient's DNA to identify the specific expansion of the CAG trinucleotide repeat in the ATXN3 gene that is indicative of SCA3. Early diagnosis through this genetic testing is crucial for management and treatment planning, as well as for providing genetic counseling to affected families, helping them understand the risk of transmission to future generations.
The BEAN1 gene is associated with Spinocerebellar Ataxia Type 31 (SCA31), a neurodegenerative disorder characterized by progressive loss of coordination, speech difficulties, and eye movement abnormalities. This condition is inherited in an autosomal dominant manner, meaning that an individual only needs a single copy of the altered gene from one parent to be affected.
DNA Labs UAE offers a genetic test specifically designed to detect mutations in the BEAN1 gene that are responsible for SCA31. This test is crucial for individuals with a family history of the disorder or those exhibiting symptoms, as it can provide a definitive diagnosis. Early detection through genetic testing can aid in managing symptoms, although there is currently no cure for SCA31.
The cost of the BEAN1 Gene Spinocerebellar Ataxia Type 31 Autosomal Dominant Genetic Test at DNA Labs UAE is 4400 AED. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of genetic alterations in the BEAN1 gene. Results from this test can help guide treatment decisions and allow for genetic counseling regarding the risk of passing the condition on to future generations.
The TGM6 Gene Spinocerebellar Ataxia Type 35 (SCA35) Autosomal Dominant Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the TGM6 gene, which are associated with Spinocerebellar Ataxia Type 35. SCA35 is a neurodegenerative disorder characterized by a wide range of symptoms including coordination and balance difficulties, speech problems, and a gradual deterioration of motor skills. This condition is inherited in an autosomal dominant manner, meaning that an individual only needs a single copy of the mutated gene from one parent to be affected.
The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect the presence of specific mutations in the TGM6 gene. It is a crucial tool for families with a history of SCA35, as it can provide definitive diagnosis of the condition, inform about the risk of passing the gene to offspring, and assist in the management and treatment planning for affected individuals.
The cost of the TGM6 Gene Spinocerebellar Ataxia Type 35 Autosomal Dominant Genetic Test at DNA Labs UAE is 4400 AED. This investment in genetic testing can offer invaluable information for affected individuals and their families, guiding healthcare decisions and providing insights into the genetic underpinnings of their condition.
The NOP56 gene is associated with Spinocerebellar Ataxia Type 36 (SCA36), a neurological disorder characterized by progressive coordination and balance difficulties due to cerebellar degeneration. This condition is inherited in an autosomal dominant manner, meaning that having just one copy of the altered gene in each cell is sufficient to cause the disorder.
DNA Labs UAE offers a specialized genetic test to identify mutations in the NOP56 gene, aiding in the diagnosis of SCA36. This test is crucial for individuals with a family history of the condition or those exhibiting symptoms, as it provides definitive genetic evidence of SCA36. Early diagnosis through genetic testing can facilitate better management and intervention strategies, potentially improving quality of life.
The cost of the NOP56 gene test for Spinocerebellar Ataxia Type 36 at DNA Labs UAE is 4400 AED. This investment includes the collection of a DNA sample, usually through a blood draw or cheek swab, and comprehensive analysis to detect the presence of specific genetic mutations associated with the disorder. Results from this test can also provide valuable information for family planning and the assessment of risk for offspring.
The PLEKHG4 gene is associated with Spinocerebellar Ataxia Type 4 (SCA4), a rare genetic disorder characterized by progressive problems with movement. This condition is part of a group of genetic disorders known as spinocerebellar ataxias, which are caused by degeneration of the cerebellum and spinal cord, leading to coordination and balance difficulties. SCA4 specifically is inherited in an autosomal dominant manner, meaning only one copy of the altered gene in each cell is sufficient to cause the disorder.
To diagnose SCA4, genetic testing is crucial. DNA Labs UAE offers a specific genetic test that identifies mutations in the PLEKHG4 gene, which can confirm a diagnosis of Spinocerebellar Ataxia Type 4. This test is particularly important for individuals with a family history of the condition or those exhibiting symptoms related to coordination and balance.
The cost of the PLEKHG4 Gene Spinocerebellar Ataxia Type 4 Autosomal Dominant Genetic Test at DNA Labs UAE is 4400 AED. This test is a significant step towards a definitive diagnosis, enabling affected individuals and their families to understand their condition better and manage it more effectively through appropriate therapeutic interventions and genetic counseling.
